Poster Presentations on PARP7 Inhibitor and Bispecific Antibody ADCs
"Dong-A ST's Research Capabilities Proven on the Global Stage"

Dong-A ST announced on March 25 that, together with its subsidiary Aptys, a company specializing in antibody-drug conjugates (ADCs), it will present a total of nine cancer drug research outcomes at the American Association for Cancer Research (AACR 2026) to be held in San Diego, USA from April 17 to April 22, 2026 (local time).


At this conference, Dong-A ST plans to release various preclinical oncology research results, including its own PARP7 inhibitor in development, an EGFR-targeting protein degrader jointly developed with HK inno.N, and a bispecific antibody ADC under joint development with Aptys.

Dong-A ST to Present Nine Cancer Drug Research Outcomes at AACR 2026 View original image

Regarding the PARP7 inhibitor, two poster presentations will be made: one on a novel PARP7 inhibitor that induces immune activation and tumor growth suppression, and another on the dual mechanism of PARP7 inhibition leading to strong antitumor activity.


Concerning the EGFR-targeting protein degrader jointly developed with HK inno.N, two posters will be presented: one on the antitumor efficacy and safety of the mutation-selective EGFR degrader (SC3613) for EGFR TKI-resistant non-small cell lung cancer (NSCLC), and another on the allosteric EGFR degrader (SC3499) designed to overcome osimertinib resistance.


For the bispecific antibody ADC cancer drugs being co-developed with Aptys, five posters will be presented, including: evaluation of immune-mediated antitumor activity and combination potential with immuno-oncology drugs for CLDN18.2-targeting ADC DA-3501; a NECTIN4 and PD-L1 bispecific antibody ADC combining immune checkpoint inhibition and targeted cytotoxicity for treating urothelial carcinoma and squamous cell lung carcinoma; overcoming gastric cancer tumor heterogeneity with an eKiH-based CLDN18.2 and HER2 bispecific antibody ADC; overcoming solid tumor resistance with an eKiH-based HER2 and AXL bispecific antibody ADC; and optimal targeting of heterogeneous tumors using a bispecific antibody ADC that incorporates an improved heterodimerization platform and precision payload conjugation technology.



A Dong-A ST representative stated, "This AACR presentation will serve as an opportunity to demonstrate Dong-A ST's research capabilities on the global stage based on a diverse anticancer pipeline and precision targeted therapy strategies," adding, "We will continue to expand our next-generation anticancer drug portfolio, including bispecific antibody ADCs, through ongoing collaboration with Aptys."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing